Tricyclic heterocyclic compounds useful as inhibitors of TNF

US10308652B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Stephen T. Wrobleski · Whitehouse Station, US
• Gregory D. Brown · Lansdale, US
• Shuqun Lin · Newtown, US
• Jingwu Duan · Yardley, US
• Zhonghui Lu · King of Prussia, US
• Murali T. G. Dhar · Newtown, US
• Hai-Yun Xiao · Montgomery, US
• Andrew J. Tebben · New Hope, US

Key dates

• Filing date: Mar 17, 2016
• Grant date: Jun 4, 2019
• Expiry date: Mar 17, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/147
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is N; W is: —(CR3R3)2-5-, —(CR3R3)x-Y—(CR3R3)y-, —Y—(CR3R3)2-3-Y—, —CR3R3-Y—(CR3R3)2-Y—, —Y—(CR3R3)2-Y—CR3R3-; and Y, R1, R2, R3, R5, R6, R8, x, and y are define herein. Also disclosed are methods of using such compounds as modulators of TNFα, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.